Tumors with high PD-L1 expression and the presence of CD8+ TILs are classified as tumor microenvironment immune type I (TMIT-I), a immunologically ‘hot’ subtype that would likely benefit from anti-PD-1/PD-L1 therapies (6). The gene discussed is CD8A; the disease is neoplasm.